Development and Evaluation of Rhenium-188-labeled Radioactive Stents for Restenosis Therapy and Development of Strategies for Radiolabeling Brachytherapy Sources with Palladium-103
This project involved collaboration between InnerDyne, Inc., and radiopharmaceutical research programs at the Oak Ridge National Laboratory (ORNL) and Brookhaven National Laboratory (BNL) which explored new strategies for the development and animal testing of radioactive rhenium-188-labeled implantable stent sources for the treatment of coronary restenosis after angioplasty and the development of chemical species radiolabeled with the palladium-103 radioisotope for the treatment of cancer. Rhenium-188 was made available for these studies from radioactive decay of tungsten-188 produced in the ORNL High Flux Isotope Reactor (HFIR). Stent activation and coating technology was developed and provided by InnerDyne, Inc., and stent radiolabeling technology and animal studies were conducted by InnerDyne staff in conjunction with investigators at BNL. Collaborative studies in animals were supported at sites by InnerDyne, Inc. New chemical methods for attaching the palladium-103 radioisotope to bifunctional chelate technologies were developed by investigators at ORNL.
- Research Organization:
- Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
- Sponsoring Organization:
- US Department of Energy (US)
- DOE Contract Number:
- AC05-00OR22725
- OSTI ID:
- 814392
- Report Number(s):
- C/ORNL98-0502; TRN: US0304250
- Resource Relation:
- Other Information: PBD: 27 Apr 2001
- Country of Publication:
- United States
- Language:
- English
Similar Records
Intraarterial irradiation with rhenium-188 for inhibition of restenosis after PTCA - strategy and evaluation of Re-188-species for rapid urinary excretion
Post-stenting Intravascular Brachytherapy Trials on Hypercholesterolemic Rabbits Using 32P Liquid Sources: Implications for Prevention of In-Stent Restenosis